triple glp 1 Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports Triple Agonists for Diabetes: Why

[DOI] [PubMed] [Google Scholar] 122.Xie Y., Choi T., Al-Aly Z

Acute pancreatitis during GLP-1 receptor agonist treatment: a case report

Monitoring and follow-up are essential during the initial treatment period

Guszczyk, A., Plizga, J., Makowicz, A., Kopczyska, E., Szpulak, A., Fraczuk, A., & Karkos, P

The most common side effects are acid reflux, constipation, fatigue, headaches, indigestion, mild nausea, and vomiting, which Saleh says are often eliminated or lessened as the medication stays in the body and you shift your lifestyle and eating habits. To minimize these side effects, avoid foods that are spicy or high in fat, and eat smaller, more frequent meals